Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 4/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763450 | 0.85 | GRIA2 (0.32) | GRIA2GRIA4GRIA1GRIA3PDE4D | |
| SCHEMBL2921927 | 0.83 | GRIA1 (0.33) | ESR2PTPN5GRIA1GRIA3PDE4D | |
| SCHEMBL3672343 | 0.80 | PIM1 (0.38) | ESR2GRIA1GRIA3PDE4D | |
| SCHEMBL5992119 | 0.78 | MCL1 (0.43) | ESR2CTSAPTPN5PRMT5WDR77 | |
| SCHEMBL3676538 | 0.78 | PTPRC (0.39) | ESR2GRIA1GRIA3PDE4DGABRA1 | |
| SCHEMBL3681524 | 0.77 | CYP11B1 (0.45) | ESR2PTPN5GRIA1GRIA3PDE4D | |
| SCHEMBL1882225 | 0.76 | GRIA1 (0.57) | ESR2GRIA2GRIA4GRIA1GRIA3 | |
| SCHEMBL3667717 | 0.74 | PGR (0.44) | GRIA2GRIA4 | |
| SCHEMBL2918046 | 0.73 | GRIA1 (0.56) | GRIA1GRIA3PDE4DGABRA1GABRG2 | |
| Water SCHEMBL4777578 | 0.73 | GRIA1 (0.56) | GRIA1GRIA3PDE4DGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164487-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164488-A1 | AMPA RECEPTOR ANTAGONISTS AND ALDOSE REDUCTASE INHIBITORS FOR NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164489-A2 | COMBINATION OF AMPA RECEPTOR ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2131828-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | Eisai R&D Management Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009054544-A1 | AMPA RECEPTOR ANTAGONISTS FOR PARKINSON'S DISEASE AND MOVEMENT DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009011411-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011410-A1 | AMPA RECEPTOR ANTAGONISTS AND ALDOSE REDUCTASE INHIBITORS FOR NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011412-A2 | COMBINATION OF AMPA RECEPTOR ANTAGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008111590-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-18 | — | — | WO | disclosed |
| US-20060276510-A1 | Dihydropyridine compounds and compositions for headaches | EISAI CO. LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276510-A1 | Dihydropyridine compounds and compositions for headaches | QDPR, ACHE, HNMT | ESR2 4324/4885GRIA2 1942/4885GRIA4 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.